Eagle's Eye View: Your Weekly CV Update From ACC.org American College of Cardiology

In this week’s View, Dr. Eagle explores stroke and bleeding risk in patients with atrial fibrillation and a CHA2DS2-VASC risk score of 1. He then discusses the important key points to remember in the recently released 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. Finally, Dr. Eagle examines the potential value of using high-sensitivity cardiac troponin as a cardiac biomarker to predict preeclampsia. 

 

Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle explores a meta-analysis of direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation. He then discusses a 20-year study of sudden cardiac death in National Collegiate Athletic Association athletes. Finally, Dr. Eagle examines the cardiovascular effects of novel weight loss therapies. 

Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle explores the role of inflammation as a predictor of coronary risk. He then discusses the safety and efficacy of renal denervation in patients taking antihypertensive medications. Finally, Dr. Eagle examines amiodarone and pulmonary toxicity in atrial fibrillation. 

Subscribe to Eagle’s Eye View  

Drs. Kim Eagle, Dharam Kumbhani, Payal Kohli, and Ajay Kirtane review the late-breaking science from the American Heart Association Scientific Sessions 2023 including ESPIRIT (0:34), MINT (3:54), ORFAN (8:25), ARISE and STREAM-2 (11:23).  The ACC is providing coverage of the latest science being presented at the AHA Scientific Sessions in Philadelphia. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage Page linked here.  Follow the ACC on Social Media and use the hashtag #AHA23.

Drs. Kim Eagle, Dharam Kumbhani, Payal Kohli, and Ajay Kirtane review the late-breaking clinical trials from day 2, Sunday, November 12 at the American Heart Association Scientific Sessions 2023 including AZAELEA-TIMI 71 (0:38), ARTESIA (5:07) and REPRIEVE (7:52).  The ACC is providing coverage of the latest science being presented at the AHA Scientific Sessions in Philadelphia. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage Page linked here.  Follow the ACC on Social Media and use the hashtag #AHA23.

Drs. Kim Eagle, Dharam Kumbhani, Payal Kohli, and Ajay Kirtane review the first day of late-breaking clinical trials at AHA 2023 for Saturday, November 11, including SELECT (0:35), DAPA MI (4:17), and ORBITA2 (7:45). 

 Subscribe to Eagle’s Eye View